Adalvo announces the successful DCP approval for Dalbavancin 500mg Powder for concentrate for solution for infusion.
This niche antibiotic has been developed based on the reference brand Xydalba (EU) and is indicated in the treatment of acute bacterial skin and skin structure infections.
The product sold $260Mn globally in 2023, with a Global 3Y CAGR of 12%, according to IQVIA.
We believe Adalvo is among Europe's first wave of companies to secure generic approval for Xydalba (EU) and will be ready for launch on Day-1 upon the expiry of market exclusivity in Europe.
The development of Dalbavancin showcases Adalvo's capability to host a diverse and comprehensive anti-infectives portfolio.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!